297 filings
Page 3 of 15
8-K
hi1y 70zng6sv4od2luo
9 Sep 21
Amendments to Articles of Incorporation or Bylaws
4:19pm
8-K
ql8 cmnmb
27 Aug 21
Completion of Acquisition or Disposition of Assets
8:47am
8-K
iohldz3y
12 Aug 21
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022
10:57am
8-K
ns55sgsjnl0
23 Jul 21
Other Events
8:43am
8-K
wv6 19ib1123
21 Jul 21
Other Events
5:17pm
8-K
7mx 80s2q5fsh
22 Jun 21
Acasti Pharma Provides Fiscal 2021 Year-End Business Update
7:00am
8-K
c87ix2lcy
17 May 21
Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance
7:11am
8-K
6gelz
7 May 21
Entry into a Material Definitive Agreement
7:09am
8-K
9ka99fa9q6ga
9 Mar 21
Acasti Pharma Provides Update on Recent Financing Activities
12:00am
8-K
r7w521c
9 Feb 21
Acasti Pharma Announces Results for Third Quarter of Fiscal 2021
4:35pm
8-K
1kul9z28 ap
27 Jan 21
Acasti Pharma Provides Update on Recent Financing Activities
7:35am
8-K
cs22dw
4 Dec 20
Other Events
8:00am
8-K
otybhvced9uou
16 Nov 20
Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021
7:05am
8-K
i4j tk47admo
7 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
8-K
dkxz0zbpo
2 Oct 20
Amendments to Articles of Incorporation or Bylaws
3:39pm
8-K
957ucbje 18
29 Sep 20
Acasti Announces Review Process of Strategic Alternatives
8:19am
8-K
elrkd8296j4 ah
17 Sep 20
Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
9:54pm
8-K
3rfg5c 8r66701ab
11 Sep 20
Acasti Announces Filing and Mailing of Information Circular and Change in Record Date
7:00am
8-K
7aycoy8x
31 Aug 20
Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia
4:05pm
8-K
zxjacw7v8f5ivzx50s
13 Aug 20
Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021
8:30am